CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it will be added as a member of the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap Indexes at the close of market today, December 20, 2013, as Russell Investments reconstitutes its comprehensive family of global indexes.
Help employers find you! Check out all the jobs and post your resume.
